Oncogenic Oncology - Is There a Targeted TKI?

EJFR, ALK behave very similarly in terms of response rates to single agent TKI. I think if you show a paradigm with EJFR and ALK, I'd start feeling better about extrapolating If there's an oncogenic subgroup where it's going to be really hard for us to actually do a phase three study. We as a community in the thoracic field, I think we do need to use more CTDNA as a marker of MRD. The GI space is certainly adopting that I'd say more quickly than we have. And I would be lying if I said I haven't given adjuvant ALK Tki or consolidation ALK T